Table 4.
Age (wk) | Treatment group | The length of oviduct (cm) | The weight of oviduct (g) | The weight of ovary (g) |
---|---|---|---|---|
16 | WL | 10.07 ± 0.46 | 1.8 ± 0.17 | 0.9 ± 0.12 |
BG-YOL | 9.95 ± 0.58 | 1.9 ± 0.13 | 0.8 ± 0.07 | |
YOL | 9.17 ± 0.45 | 1.8 ± 0.11 | 0.9 ± 0.09 | |
BGL | 9.50 ± 0.31 | 1.7 ± 0.09 | 0.8 ± 0.07 | |
20 | WL | 42.42 ± 7.18b | 36.6 ± 10.08b | 19.0 ± 6.21b |
BG-YOL | 59.17 ± 3.83a | 63.3 ± 9.37a | 25.0 ± 6.46a | |
YOL | 45.67 ± 14.09b | 45.1 ± 19.42b | 20.2 ± 8.85a,b | |
BGL | 62.17 ± 4.56a | 60.6 ± 10.66a | 22.6 ± 5.46a,b |
a,bDifferent lowercase letters within a column indicate significant differences at same week of age (P < 0.05).
Data are presented as means ± SE.
Abbreviations: BG-YOL group, blue–green (435–565 nm) light at phase 1 (1 D–13 wk) followed by yellow–orange (565–630 nm) light at phase 2 (14–20 wk); BGL group, blue–green (435–565 nm) light at phase 1 (1 D–13 wk) and phase 2 (14–20 wk); LED, light-emitting diode; WL group, white (400–700 nm) light at phase 1 (1 D–13 wk) and phase 2 (14–20 wk); YOL group, yellow–orange LED (565–630 nm) light at phase 1 (1 D–13 wk) and phase 2 (14–20 wk).